Verici Dx PLC Sustainability Reports
Verici Dx plc develops advanced RNA signature-based transcriptomic tests for personalized patient and organ response risk management in kidney transplantation. Its suite of blood-based diagnostic and prognostic tests includes Clarava, Tutivia, and Protega to improve patient outcomes.
Sector: Manufacturing
Country: United Kingdom
Exchange: London Stock Exchange (AIM)
LEI: 213800FI5WE4FVQ3G645
FIGI: BBG00VZQDMK0
7 reports from 2020 to 2025